Announcements Trials
Browse Landscape

Phase

Phase 2 38Phase 1/2 8Phase 3 4Phase 1 4Phase 2/3 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1Classical hematology 1

Conditions

Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Lymphedema 1Leukemia, Myeloid, Chronic-Phase 1Leukemia, Myeloid, Acute 1Leukemia, Myeloid, Accelerated Phase 1Leukemia 1Graft vs Host Disease 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Cyclophosphamide 4vedolizumab 1thymoglobulin 1ruxolitinib 1peginterferon alfa-2b 1fludarabine phosphate 1blinatumomab 1baricitinib 1Tacrolimus 1Radiotherapy 1Photopheresis 1Methylprednisolone 1Filgrastim 1Antilymphocyte Serum 1Adrenal Cortex Hormones 1Abatacept 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Graft vs Host Disease × Tacrolimus × Clear all
NCT00004255 2013-07-10

Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

National Cancer Institute (NCI)

Phase 2/3 Completed
Classical hematologyLymphoidMyeloidOther hematologic neoplasm

Anemia, Refractory, with Excess of Blasts, Graft vs Host Disease, Leukemia, Myelodysplastic Syndromes, Leukemia, Myeloid, Accelerated Phase, Leukemia, Myeloid, Chronic-Phase, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡